Keyphrases
Adult Patients
100%
Anticoagulation
63%
Bleeding Risk
60%
Mayo Clinic
54%
Von Willebrand Factor Concentrate
51%
Cerebral Infarction
45%
ADAMTS13 Protein
45%
Retrospective Cohort Study
45%
Continuous Infusion
45%
Care Pathway
45%
Consensus Statement
45%
Transfusional Iron Overload
45%
Fanconi Syndrome
45%
FLLL32
45%
Alternative Complement Pathway
45%
Hematological Parameters
45%
COVID-19
45%
Remission
45%
Type 3 Von Willebrand Disease
45%
Critically Ill Patients
45%
Thrombotic Microangiopathy
45%
Deferasirox
45%
Joint Injection
45%
Emicizumab
45%
Silent Cerebral Infarction
45%
Myeloid Sarcoma
45%
Von Willebrand Disease
45%
Direct Oral Anticoagulants
45%
Thrombosis with Thrombocytopenia Syndrome
45%
Survival Analysis
45%
Arthrocentesis
45%
Comparative Analysis
45%
Cryptogenic Stroke
45%
Cognitive Impairment
38%
Immune Thrombocytopenic Purpura
37%
ADAMTS13
34%
Thrombotic Thrombocytopenic Purpura
34%
Microangiopathic Hemolytic Anemia
31%
Von Willebrand Factor
29%
Joint Aspiration
27%
Confidence Interval
25%
Bleeding
24%
Recurrent Stroke
22%
Acute Myeloid Leukemia
22%
Hematological Abnormalities
22%
Viral Illness
20%
Thrombocytopenia
20%
Survivors
19%
Differential Diagnosis
18%
Bleeding Complications
18%
Medicine and Dentistry
Microangiopathy
96%
Von Willebrand Disease
90%
COVID-19
90%
Thrombotic Thrombocytopenic Purpura
79%
Anticoagulation
72%
Thrombocytopenia
68%
Bleeding
63%
Von Willebrand Factor
58%
Thrombosis
56%
Disease
53%
Von Willebrand Factor Cleaving Proteinase
49%
Deferasirox
45%
Direct Oral Anticoagulant
45%
Iron Overload
45%
Fanconi Syndrome
45%
Complement Alternative Pathway
45%
Retrospective Cohort Study
45%
Proteasome Inhibitor
45%
Care Pathway
45%
Brain Infarction
45%
Emicizumab
45%
Apoplexy
45%
Joint Injection
45%
Myeloid Sarcoma
45%
Arthrocentesis
45%
Continuous Infusion
45%
Joint Aspiration
27%
Differential Diagnosis
22%
Acute Myeloid Leukemia
22%
Intensive Care Unit
21%
Viral Disease
20%
COVID-19 Vaccine
20%
Drug Therapy
18%
COVID-19 Vaccination
15%
Outpatient
14%
Platelet
14%
Immunoglobulin
13%
Monoclonal Gammopathy of Undetermined Significance
13%
Ciclonicate
12%
Major Bleeding
12%
Hazard Ratio
12%
3 (6 Bromo 2 Pyridinyl) 2 Cyano N (1 Phenylethyl)acrylamide
11%
Tubular Dysfunction
11%
Clinical Pathway
11%
Diagnostic Test
11%
Ischemia
11%
COVID-19 Vaccine Janssen
10%
Heparin-Induced Thrombocytopenia
10%
Adverse Event
10%
Anticoagulant Therapy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Von Willebrand Disease
90%
Von Willebrand Factor
58%
Thrombocytopenia
45%
Microangiopathy
45%
Proteasome Inhibitor
45%
Vaccination Policy
45%
Thrombosis
45%
Syndrome
45%
Emicizumab
45%
COVID-19 Vaccine
25%
Immunoglobulin
13%
Monoclonal Immunoglobulinemia
13%
Ciclonicate
12%
Heparin Induced Thrombocytopenia
10%
Adverse Event
10%
3 (6 Bromo 2 Pyridinyl) 2 Cyano N (1 Phenylethyl)acrylamide
9%
Epileptic Absence
6%
Bleeding Disorder
6%
Metrorrhagia
6%
Alloantibody
6%
Haemophilia A
6%
Vein Embolism
5%
Lung Embolism
5%
Antiplatelet
5%
Brain Ischemia
5%
Calcium Ion
5%
Heart Infarction
5%
Cerebral Sinus Thrombosis
5%
Enzyme-Linked Immunosorbent Assay
5%
